Exposing the interplay between enzyme turnover, protein dynamics and the membrane environment in monoamine oxidase B

Hannah B. L. Jones, Rory M Crean, Anna Mullen, Emanuele Kendrick, Steven D. Bull, Stephen A. Wells, David Ross Carbery, Fraser Macmillan, Marc W. Van Der Kamp, Christopher Roland Pudney

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
11 Downloads (Pure)


There is an increasing realization that structure-based drug design may show improved success rates by understanding the ensemble of conformations and sub-states accessible to an enzyme and how the environment affects this ensemble. Human monoamine oxidase B (MAO-B) catalyzes the oxidation of amines and is inhibited for the treatment of both Parkinson’s disease and depression. Despite its clinical importance, its catalytic mechanism remains unclear and routes to drugging this target would be valuable and relevant. Evidence of a radical in either the transition state or resting state of MAO-B is present throughout the literature, and is suggested to be a flavin semiquinone, a tyrosyl radical or both. Here we see evidence of a resting state flavin semiquinone, via absorption redox studies and electron paramagnetic resonance, suggesting that the anionic semiquinone is biologically relevant. Based on enzyme kinetic studies, enzyme variants and molecular dynamics simulations we find evidence for the crucial importance of the membrane environment in mediating the activity of MAO-B and that this mediation is related to effects on the protein dynamics of MAO-B. Further, our MD simulations identify a hitherto undescribed entrance for substrate binding, membrane modulated substrate access, and indications for half-site reactivity: only one active site is accessible to binding at a time. Our study combines both experimental and computational evidence to illustrate the subtle interplay between enzyme activity, protein dynamics and the immediate membrane environment. Understanding key biomedical enzymes to this level of detail will be crucial to inform strategies (and binding sites) for rational drug design for these drug targets.
Original languageEnglish
Pages (from-to)2362–2372
Issue number18
Early online date9 Apr 2019
Publication statusPublished - 7 May 2019

Cite this